Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
This article was originally published in The Pink Sheet Daily
FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.
You may also be interested in...
The Swiss company, known for its pulmonary hypertension dominance, welcomes awareness-raising competition from new entrants like Gilead, CFO Oakley says.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Ambrisentan beats out Encysive's Thelin in race for FDA approval for treatment of pulmonary arterial hypertension.